The Phase 3 clinical trial investigating CagriSema (cagrilintide B and semaglutide I) for people with Type 2 Diabetes reached its primary completion on 2025-10-01. This study, NCT06323174, aimed to assess how much CagriSema lowers blood sugar and body weight compared to placebo.
Background
CagriSema is an investigational medicine being studied for its potential to lower blood sugar and body weight in individuals with Type 2 Diabetes. It combines cagrilintide and semaglutide, which are being compared against a placebo in this trial.
Trial design
The study, identified as NCT06323174, is a Phase 3 trial with an enrollment of 189 participants. It is designed to evaluate CagriSema in individuals diagnosed with Type 2 Diabetes who are treated with diet and exercise. Participants were randomized to receive either CagriSema (a combination of cagrilintide and semaglutide) or a placebo. The primary objective of the study is to determine the extent to which CagriSema lowers blood sugar and body weight compared to placebo.
What this means
The primary completion of this Phase 3 trial for CagriSema signifies that the collection of data for the study's main objectives has concluded. Researchers will now proceed with data analysis to determine the efficacy of CagriSema in lowering blood sugar and body weight in people with Type 2 Diabetes. The upcoming results will provide critical insights into the potential role of this investigational medicine.
Source
The information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The record for study NCT06323174, titled "A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise," was updated on 2025-10-01 on clinicaltrials.gov.